Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAMSARC: Pasireotide Maintenance in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
2024-511935-86-00Phase 2Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in synovial sarcoma (SS) and desmoplastic small round cell tumor (DSRCT), sponsored by Heidelberg University Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
pasireotide LAR
03
Conditions
synovial sarcoma (SS)desmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on 2024-511935-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511935-86-00.